331 related articles for article (PubMed ID: 21220306)
1. Thyrotrophin receptor signaling dependence of Braf-induced thyroid tumor initiation in mice.
Franco AT; Malaguarnera R; Refetoff S; Liao XH; Lundsmith E; Kimura S; Pritchard C; Marais R; Davies TF; Weinstein LS; Chen M; Rosen N; Ghossein R; Knauf JA; Fagin JA
Proc Natl Acad Sci U S A; 2011 Jan; 108(4):1615-20. PubMed ID: 21220306
[TBL] [Abstract][Full Text] [Related]
2. Thyrotropin signaling confers more aggressive features with higher genomic instability on BRAF(V600E)-induced thyroid tumors in a mouse model.
Orim F; Bychkov A; Shimamura M; Nakashima M; Ito M; Matsuse M; Kurashige T; Suzuki K; Saenko V; Nagayama Y; Yamashita S; Mitsutake N
Thyroid; 2014 Mar; 24(3):502-10. PubMed ID: 23924149
[TBL] [Abstract][Full Text] [Related]
3. TSH overcomes Braf(V600E)-induced senescence to promote tumor progression via downregulation of p53 expression in papillary thyroid cancer.
Zou M; Baitei EY; Al-Rijjal RA; Parhar RS; Al-Mohanna FA; Kimura S; Pritchard C; Binessa HA; Alzahrani AS; Al-Khalaf HH; Hawwari A; Akhtar M; Assiri AM; Meyer BF; Shi Y
Oncogene; 2016 Apr; 35(15):1909-18. PubMed ID: 26477313
[TBL] [Abstract][Full Text] [Related]
4. Postnatal expression of BRAFV600E does not induce thyroid cancer in mouse models of thyroid papillary carcinoma.
Shimamura M; Nakahara M; Orim F; Kurashige T; Mitsutake N; Nakashima M; Kondo S; Yamada M; Taguchi R; Kimura S; Nagayama Y
Endocrinology; 2013 Nov; 154(11):4423-30. PubMed ID: 23970782
[TBL] [Abstract][Full Text] [Related]
5. BRAF V600E and decreased NIS and TPO expression are associated with aggressiveness of a subgroup of papillary thyroid microcarcinoma.
Bastos AU; Oler G; Nozima BH; Moysés RA; Cerutti JM
Eur J Endocrinol; 2015 Oct; 173(4):525-40. PubMed ID: 26338373
[TBL] [Abstract][Full Text] [Related]
6. Expression of iodine metabolism genes in human thyroid tissues: evidence for age and BRAFV600E mutation dependency.
Espadinha C; Santos JR; Sobrinho LG; Bugalho MJ
Clin Endocrinol (Oxf); 2009 Apr; 70(4):629-35. PubMed ID: 18710471
[TBL] [Abstract][Full Text] [Related]
7. Cross-regulation between oncogenic BRAF(V600E) kinase and the MST1 pathway in papillary thyroid carcinoma.
Lee SJ; Lee MH; Kim DW; Lee S; Huang S; Ryu MJ; Kim YK; Kim SJ; Kim SJ; Hwang JH; Oh S; Cho H; Kim JM; Lim DS; Jo YS; Shong M
PLoS One; 2011 Jan; 6(1):e16180. PubMed ID: 21249150
[TBL] [Abstract][Full Text] [Related]
8. KRAS(G12D)-mediated oncogenic transformation of thyroid follicular cells requires long-term TSH stimulation and is regulated by SPRY1.
Zou M; Baitei EY; Al-Rijjal RA; Parhar RS; Al-Mohanna FA; Kimura S; Pritchard C; BinEssa H; Alanazi AA; Alzahrani AS; Akhtar M; Assiri AM; Meyer BF; Shi Y
Lab Invest; 2015 Nov; 95(11):1269-77. PubMed ID: 26146959
[TBL] [Abstract][Full Text] [Related]
9. Suppression of BRAF/MEK/MAP kinase pathway restores expression of iodide-metabolizing genes in thyroid cells expressing the V600E BRAF mutant.
Liu D; Hu S; Hou P; Jiang D; Condouris S; Xing M
Clin Cancer Res; 2007 Feb; 13(4):1341-9. PubMed ID: 17317846
[TBL] [Abstract][Full Text] [Related]
10. Mutationally activated BRAF(V600E) elicits papillary thyroid cancer in the adult mouse.
Charles RP; Iezza G; Amendola E; Dankort D; McMahon M
Cancer Res; 2011 Jun; 71(11):3863-71. PubMed ID: 21512141
[TBL] [Abstract][Full Text] [Related]
11. p53 constrains progression to anaplastic thyroid carcinoma in a Braf-mutant mouse model of papillary thyroid cancer.
McFadden DG; Vernon A; Santiago PM; Martinez-McFaline R; Bhutkar A; Crowley DM; McMahon M; Sadow PM; Jacks T
Proc Natl Acad Sci U S A; 2014 Apr; 111(16):E1600-9. PubMed ID: 24711431
[TBL] [Abstract][Full Text] [Related]
12. Clinical Manifestations and Gene Expression in Patients with Conventional Papillary Thyroid Carcinoma Carrying the BRAF(V600E) Mutation and BRAF Pseudogene.
Lin JD; Fu SS; Chen JY; Lee CH; Chau WK; Cheng CW; Wang YH; Lin YF; Fang WF; Tang KT
Thyroid; 2016 May; 26(5):691-704. PubMed ID: 26914762
[TBL] [Abstract][Full Text] [Related]
13. IL-12 immunotherapy of Braf(V600E)-induced papillary thyroid cancer in a mouse model.
Parhar RS; Zou M; Al-Mohanna FA; Baitei EY; Assiri AM; Meyer BF; Shi Y
Lab Invest; 2016 Jan; 96(1):89-97. PubMed ID: 26501867
[TBL] [Abstract][Full Text] [Related]
14. Thyroid stimulating hormone increases iodine uptake by thyroid cancer cells during BRAF silencing.
Kleiman DA; Buitrago D; Crowley MJ; Beninato T; Veach AJ; Zanzonico PB; Jin M; Fahey TJ; Zarnegar R
J Surg Res; 2013 Jun; 182(1):85-93. PubMed ID: 22998776
[TBL] [Abstract][Full Text] [Related]
15. Epigenetic silencing of TSHR gene in thyroid cancer patients in relation to their BRAF V600E mutation status.
Khan MS; Pandith AA; Masoodi SR; Wani KA; Ul Hussain M; Mudassar S
Endocrine; 2014 Nov; 47(2):449-55. PubMed ID: 24927793
[TBL] [Abstract][Full Text] [Related]
16. Uncommon BRAF mutations in the follicular variant of thyroid papillary carcinoma: New insights.
Rossi ED; Martini M; Bizzarro T; Capodimonti S; Cenci T; Lombardi CP; Pontecorvi A; Fadda G; Larocca LM
Cancer Cytopathol; 2015 Oct; 123(10):593-602. PubMed ID: 26230187
[TBL] [Abstract][Full Text] [Related]
17. Progression of BRAF-induced thyroid cancer is associated with epithelial-mesenchymal transition requiring concomitant MAP kinase and TGFβ signaling.
Knauf JA; Sartor MA; Medvedovic M; Lundsmith E; Ryder M; Salzano M; Nikiforov YE; Giordano TJ; Ghossein RA; Fagin JA
Oncogene; 2011 Jul; 30(28):3153-62. PubMed ID: 21383698
[TBL] [Abstract][Full Text] [Related]
18. Epigenetically upregulated WIPF1 plays a major role in BRAF V600E-promoted papillary thyroid cancer aggressiveness.
Zhang T; Shen X; Liu R; Zhu G; Bishop J; Xing M
Oncotarget; 2017 Jan; 8(1):900-914. PubMed ID: 27863429
[TBL] [Abstract][Full Text] [Related]
19. Prohibitin is overexpressed in papillary thyroid carcinomas bearing the BRAF(V600E) mutation.
Franzoni A; Dima M; D'Agostino M; Puppin C; Fabbro D; Loreto CD; Pandolfi M; Puxeddu E; Moretti S; Celano M; Bruno R; Filetti S; Russo D; Damante G
Thyroid; 2009 Mar; 19(3):247-55. PubMed ID: 19207009
[TBL] [Abstract][Full Text] [Related]
20. BRAF
Hernandez BY; Rahman M; Loo LWM; Chan OTM; Horio D; Morita S; Bryant-Greenwood G
J Cancer Res Clin Oncol; 2021 Jan; 147(1):183-194. PubMed ID: 32995956
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
